In particular, ICAM1, THY1, and CXCR4 were higher expressed in GC patients in Stage II–IV, compared with that in Stage-I patients (P < 0.01) (Figure 2A); and they were expressed higher in Grade-3 tumors than that in Grade-2 tumors (P < 0.01) (Figure 2B). Here, ICAM1 is linked to gastric cancer.